GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-15| Trials & Approvals

GSK’s Meningococcal Combination Vaccine Clears All Primary Endpoints In Phase 3

by Joy Lin
Share To

GSK has revealed positive results from the Phase 3 trial of its MenABCWY combination vaccine candidate, putting it one step closer to a planned regulatory filing. 

GSK’s MenABCWY vaccine combines the antigenic parts of its licensed meningococcal vaccines Bexsero (MenB) and Menveo (MenACWY), conferring protection to all five Neisseria meningitides serogroups A, B, C, W, and Y. It is given in two doses spaced six months apart in healthy participants aged 10-25 years. 

Related Article: Astellas Clears Primary Endpoints In Prostate Cancer And Menopause Trials

Combination Vaccine Achieves All 11 Primary Endpoints in Phase 3

Invasive meningococcal disease (IMD) is a major cause of meningitis and sepsis. While uncommon, it can be serious enough to cause death, typically amongst healthy children and adolescents. Even when victims survive, they might suffer long-term consequences ranging from nervous system problems to amputations. 

GSK has been pushing for a combination vaccine that could guard against the five N. meningitides serogroups that account for nearly all IMD cases globally. In the US, two separate vaccines which require four injections are required to receive full protection. This immunization regimen, coupled with low awareness of the disease, may lead to inadequate coverage rates, said GSK. If its MenABCWY combination vaccine is approved, it could lead to a simplified immunization schedule while providing the broadest serogroup coverage. 

In the MenABCWY Phase 3 trial, which enrolled around 3,650 individuals from around the world, the 5-in-1 vaccine candidate met all 11 primary endpoints and demonstrated statistical non-inferiority compared to Bexsero and Menveo. Safety-wise, the candidate was similar to Bexsero and Menveo. 

“These statistically significant Phase 3 data are a very encouraging step toward reducing the incidence of meningococcal disease,” said Tony Wood, Chief Scientific Officer at GSK. 

“In the US, routine use of a 5-in-1 meningococcal vaccine with a two-dose regimen in adolescents at 16 to 18 years of age, just before this disease’s incidence peak, could drive significant public health impact. In addition, our 5-in-1 meningococcal vaccine candidate builds on our global leadership in meningococcal vaccines and commitment to innovation.”

The full Phase 3 data will be reviewed with regulators, which could support the supplemental Biologics License Application for Bexsero. This is because the trial serves as both Bexsero’s confirmatory trial and the Phase 3 trial for MenABCWY. Detailed results will be presented in a peer-reviewed publication and at future scientific meetings.  

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
GSK Secures Approval From Chinese NMPA for Nucala, its Add-On-Therapy to Treat CRSwNP
2025-01-07
GSK Expands Arexvy Approval to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
2024-12-02
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top